Idelalisib(continued)
▶Idelalisibis predicted to increase the exposure totoremifene.
oTheoretical
▶Idelalisibis predicted to increase the exposure totrabectedin.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15p. 850
▶Idelalisibis predicted to moderately increase the exposure to
trazodone. Avoid or adjust dose.oStudy
▶Idelalisibis predicted to increase the exposure toulipristal.
Avoid if used for uterinefibroids.rStudy
▶Idelalisibis predicted to increase the exposure tovemurafenib.
rTheoretical
▶Idelalisibis predicted to increase the exposure tovenetoclax.
Avoid potent inhibitors of CYP3A4 or adjustvenetoclaxdose.
rStudy
▶Idelalisibis predicted to increase the exposure tovenlafaxine.
oStudy
▶Idelalisibis predicted to increase the exposure tovinca
alkaloids.rTheoretical→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure tovitamin D
substances(paricalcitol).oStudy
▶Idelalisibis predicted to increase the exposure tozopiclone.
Adjust dose.oTheoretical
Ifosfamide→see alkylating agents
Iloprost→seeTABLE 4p. 847 (antiplatelet effects)
Imatinib→seeTABLE 15p. 850 (myelosuppression)
▶Imatinibis predicted to increase the exposure toaldosterone
antagonists(eplerenone). Adjusteplerenonedose.rStudy
▶Imatinibis predicted to increase the exposure toalpha blockers
(tamsulosin).oTheoretical
▶Imatinibis predicted to increase the exposure toalprazolam.
rStudy
▶Imatinibis predicted to increase the exposure to
antiarrhythmics(dronedarone).rTheoretical
▶Imatinibis predicted to increase the exposure to
antiarrhythmics(propafenone). Monitor and adjust dose.
oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toimatinib. Avoid.oStudy
▶Antiepileptics(oxcarbazepine)decrease the exposure to
imatinib. Avoid.oStudy
▶Antifungals, azoles(fluconazole, posaconazole)are predicted to
increase the exposure toimatinib.oTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toimatinib.oStudy
▶Imatinibis predicted to decrease the exposure toantifungals,
azoles(isavuconazole).oTheoretical
▶Imatinibis predicted to increase the exposure toantihistamines,
non-sedating(mizolastine).rTheoretical
▶Imatinibis predicted to increase the exposure toantihistamines,
non-sedating(rupatadine). Avoid.oStudy
▶Imatinibis predicted to increase the concentration of
antimalarials(piperaquine).rTheoretical
▶Aprepitantis predicted to increase the exposure toimatinib.
oTheoretical
▶Asparaginaseis predicted to increase the risk of hepatotoxicity
when given withimatinib.rTheoretical→Also seeTABLE 15
p. 850
▶Imatinibis predicted to increase the exposure toaxitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical
▶Bosentanis predicted to decrease the exposure toimatinib.
oStudy
▶Imatinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Imatinibis predicted to increase the exposure tocabozantinib.
oTheoretical→Also seeTABLE 15p. 850
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toimatinib.oTheoretical
▶Imatinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Imatinibis predicted to increase the exposure toceritinib.
oTheoretical→Also seeTABLE 15p. 850
▶Imatinibincreases the concentration ofciclosporin.r
Study
▶Cobicistatis predicted to increase the exposure toimatinib.
oStudy
▶Imatinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Imatinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Imatinibis predicted to increase the exposure tocorticosteroids
(methylprednisolone). Monitor and adjust dose.oStudy
▶Imatinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Crisantaspaseis predicted to increase the risk of
hepatotoxicity when given withimatinib.rTheoretical→
Also seeTABLE 15p. 850
▶Imatinibis predicted to slightly increase the exposure to
darifenacin.oStudy
▶Imatinibis predicted to increase the exposure todasatinib.
rStudy→Also seeTABLE 15p. 850
▶Imatinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Imatinibis predicted to increase the exposure todopamine
receptor agonists(bromocriptine).rTheoretical
▶Imatinibis predicted to increase the concentration of
dopamine receptor agonists(cabergoline).oAnecdotal
▶Imatinibis predicted to moderately increase the exposure to
dutasteride.nStudy
▶Efavirenzis predicted to decrease the exposure toimatinib.
oStudy
▶Imatinibis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶Enzalutamideis predicted to decrease the exposure to
imatinib. Avoid.oStudy
▶Imatinibis predicted to increase the risk of ergotism when
given withergometrine.rTheoretical
▶Imatinibis predicted to increase the risk of ergotism when
given withergotamine.rTheoretical
▶Imatinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Imatinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Imatinibis predicted to increase the exposure tofesoterodine.
Adjustfesoterodinedose with moderate inhibitors of CYP3A4
in hepatic and renal impairment.nStudy
▶Imatinibis predicted to increase the exposure togefitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Grapefruit juiceis predicted to increase the exposure to
imatinib.oTheoretical
▶Imatinibis predicted to increase the concentration of
guanfacine. Adjustguanfacinedose,p. 231.oTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
toimatinib.oStudy
▶Imatinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure toimatinib.
oStudy→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure toivabradine.
Adjustivabradinedose.rTheoretical
▶Imatinibis predicted to increase the exposure toivacaftor.
Adjustivacaftordose with moderate inhibitors of CYP3A4,
p. 186.rStudy
▶Imatinibis predicted to increase the exposure tolapatinib.
oStudy
▶Imatinibis predicted to increase the exposure tolomitapide.
Avoid.oTheoretical
▶Imatinibis predicted to increase the exposure tolurasidone.
oStudy936 Idelalisib—Imatinib BNFC 2018 – 2019
Interactions|Appendix 1A1